September 28, 2017 – Janesville, WI – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,734,926. This patent is an important addition to the Company’s intellectual property, which is also protected by over 20 SHINE-owned issued and pending patents on SHINE’s novel medical isotope production process, and exclusive, world-wide licenses for the accelerator and hydrogen separation technologies.
U.S. Patent No. 9,734,926 relates to producing medical isotopes and expires December 23, 2032. This achievement demonstrates SHINE’s ongoing commitment to innovation and leadership in the medical isotope industry.
“This patent protects our technology in America, which is the largest market in the world. The technology is inherent to SHINE’s competitive advantage,” said Greg Piefer, CEO of SHINE. “SHINE’s innovations simplify the isotope production process, reduce waste associated with conventional isotope production by hundreds of times, and consequently, provide a significant reduction in cost.”
SHINE holds seven issued patents in six countries. Additionally, SHINE has exclusive, worldwide licenses for the accelerator technology, two patents managed by the Wisconsin Alumni Research Foundation, and Savannah River National Laboratory’s hydrogen purification technology.
Molybdenum-99 (Mo-99) is a radioisotope that decays into the diagnostic imaging agent technetium‑99m (Tc-99m). Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer. SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce medical isotopes, including Mo‑99.
About SHINE Medical Technologies, Inc.
Founded in 2010, SHINE is a development-stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies, as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for molybdenum-99. In 2014, SHINE announced the execution of molybdenum-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE molybdenum-99 can act as a drop-in replacement for reactor-based moly-99. In 2016, SHINE received regulatory approval to construct its facility from the Nuclear Regulatory Commission and signed a moly-99 supply agreement with HTA Co., Ltd., the largest Chinese distributor of radiopharmaceuticals. Learn more at http://shinemed.com.